Dual incretins done right: the FDA-approved benchmark that defines what GIP/GLP-1 co-agonism can achieve
Look, tirzepatide isn’t just another incretin. The whole story starts at the receptor pharmacology: GIP and GLP-1 agonism together produce a genuinely additive effect that neither receptor achieves alone. GIP engagement modulates adipose tissue metabolism and potentiates insulin secretion in a glucose-dependent fashion; GLP-1 handles central satiety signaling, gastric emptying delay, and glucagon suppression. Running both pathways simultaneously turns out to be more than the sum of its parts, and the SURMOUNT program is the evidence base that confirmed it at scale.
These arent modest numbers from a single lab. SURMOUNT-2, -3, and -4 extended the findings to T2DM populations, confirmed durability after withdrawal, and locked in the dose-response relationship. Multiple RCTs, multiple populations, consistent signal. The evidence quality here is genuinely high for a peptide compound.
What we find most interesting from a research standpoint is what the GIP component actually contributes. GLP-1 monotherapy was already well-validated before tirzepatide arrived. In a real sense, tirzepatide is the controlled experiment for what layering GIP receptor agonism adds on top of established GLP-1 biology. The GIP receptor’s role in adipose tissue, its interactions with adiponectin signaling, and the downstream effects on fat mass independent of energy intake are not fully characterized, and tirzepatide is one of the few available probes for studying that biology at clinically meaningful concentrations.
We dont think it’s breaking news anymore, though. Tirzepatide is FDA-approved, widely prescribed, and the research program is maturing fast. Novelty has a shelf life, and this compound is burning through it. Retatrutide is already in phase 2 with a triple agonist profile adding glucagon receptor activity, which makes tirzepatide look like a stepping stone in a rapidly evolving pharmacology story. Bench investigators focused purely on incretin frontier biology will want to be watching that space closely.
For investigators working on metabolic pharmacology, incretin receptor biology, adipose tissue signaling, or GLP-related satiety circuitry, tirzepatide remains one of the most useful tools available. The evidence base is unusually clean. The mechanism is well-defined. And the gap it opened between dual and single GLP-1 agonism is exactly the kind of differentiated signal that gives a research program somewhere real to go. The score reflects a compound that genuinely moved the field, even as the field is already starting to move past it.